| Autor: |
Blanco JC; Virion Systems Inc., Rockville, MD, USA. jblanco@virionsystmes.com, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN |
| Jazyk: |
angličtina |
| Zdroj: |
Human vaccines [Hum Vaccin] 2010 Jun; Vol. 6 (6), pp. 482-92. Date of Electronic Publication: 2010 Jun 01. |
| DOI: |
10.4161/hv.6.6.11562 |
| Abstrakt: |
Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants and children <1 year old, resulting in significant morbidity and mortality worldwide. There is currently no RSV vaccine. In the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine trial led to exacerbated disease upon natural infection of vaccinees, including two deaths. The causes involved in the disastrous results of these vaccine trials are still unclear but they remain the engine for searching new avenues to develop a safe vaccine that can provide long-term protection against this important pathogen. This article reviews some of the early history of RSV vaccine development,as well as more recent information on the interaction between RSV and the host innate and adaptive immune responses. A safe and efficacious vaccine for RSV will require "re-education" of the host immune response against RSV to prevent vaccine-enhanced or severe RSV disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
